Moderna, Inc. (MRNA) stock
- 1No macro events in the recency window.
- 2earnings: MRNA Q2 2026 earnings scheduled (scheduled 2026-07-31)
- 3Revenue growth 260.2% YoY, net margin -143.6%.
Factor grades
As of 2026-07-28Percentile grades within the stock’s sector, computed nightly from SEC filings. Statistical ranking, not investment advice.
Fair value estimate
Median of 3 peer-multiple estimates. Not investment advice.
- No macro events in the recency window.
- earnings: MRNA Q2 2026 earnings scheduled (scheduled 2026-07-31)
- earningsScheduled 2026-07-31MRNA Q2 2026 earnings scheduledConsensus EPS -2.12.NEUTRAL
- Revenue growth 260.2% YoY, net margin -143.6%.
- Forward P/E -13.341701, FCF $-0.0B.
- Earnings beat 0% of trailing 0 quarters.
- FMR, LLC45.7M sh · +62.85% QoQ
- Blackrock Inc.29.6M sh · -8.83% QoQ
- Vanguard Capital Management LLC22.9M sh · +100.00% QoQ
- BAILLIE GIFFORD & CO20.0M sh · -2.89% QoQ
- Capital World Investors18.7M sh · +45.76% QoQ
- No news in the recency window.
- Signal shifted from bearish since the last brief.
Key fundamentals
Trailing-twelve-month figures computed by Meaterm from SEC filings, refreshed nightly.
Related Biological Products, (No Diagnostic Substances) stocks
Frequently asked questions
What are the MRNA factor grades?
Meaterm scores Moderna, Inc. (MRNA) on four factors — valuation, growth, profitability and momentum — plus a composite. Each grade is a percentile ranking against the stock's sector, computed nightly from SEC-filed financial data. Grades are statistical rankings, not investment advice or a recommendation to trade.
How is the fair value estimate for MRNA calculated?
The estimate is the median of several peer-multiple implied values — peer P/E, EV/EBITDA, P/S and P/B applied to the company's own fundamentals — plus a sell-side consensus target when one is available. Peers come from the same industry, matched by size. It is a statistical reference point, not a price target and not investment advice.
Where does the data on this page come from?
Fundamentals and factor grades are computed by Meaterm from SEC filings and refreshed nightly. Positioning context comes from public CFTC and FINRA releases, and macro series from FRED. Every signal, grade and estimate shown is Meaterm’s own computation.
Is MRNA a good stock to invest in?
Meaterm does not answer that question. This page shows how Moderna, Inc. (MRNA) ranks statistically against sector peers on valuation, growth, profitability and momentum, and where its price sits relative to a peer-multiple estimate. Use it as research context alongside your own analysis — nothing on this page is investment advice.
How often is this page updated?
Factor grades, fundamentals and the company profile refresh nightly after each trading day. The brief layers — macro, catalysts, positioning and news — are composed when the page loads, and the fair value estimate is recomputed with recent quotes during the day.